Get all your news in one place.
100's of premium titles.
One app.
Start reading
AAP
AAP

Frost & Sullivan: Global Pharmaceutical Industry Faces a High-Stakes Reset as AI, Biologics, and Supply Resilience Redefine Growth Through 2031

New Frost & Sullivan analysis reveals that future winners will be those that can execute faster, industrialise innovation, and navigate mounting pricing and geopolitical pressures

LONDON, June 11, 2026 /PRNewswire/ -- Frost & Sullivan's latest analysis, Growth Opportunities in Global Pharmaceutical Industry, 2026, finds that the pharmaceutical industry is entering a period of profound transformation as affordability mandates, patent expiries, geopolitical fragmentation, and rapid technological advances reshape the foundations of value creation.

According to the study, traditional drivers of success are being replaced by a new set of competitive imperatives centred on execution excellence, supply resilience, AI-enabled operations, and the ability to commercialise increasingly complex therapeutic modalities at scale.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.